With increasing knowledge about oncogenic mutation of NSCLC, several effective therapeutic opinions have been developed, including a specific antibody to the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). Here, ALK is linked to non-small cell lung carcinoma.